
Deborah J. Wexler MD, MSc
Associate Professor of Medicine, Harvard Medical School; Chief, Diabetes Unit, Massachusetts General Hospital, Boston, MassachusettsDr. Deborah J. Wexler's research focuses on clinical effectiveness in type 2 diabetes. In addition, she is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.
Disclosures
Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.
Recent Contributions to PracticeUpdate:
- Impact of Neighborhoods on Diabetes Risk and Outcomes
- Food Insecurity and Diabetes
- Overview of Social Determinants of Health in the Development of Diabetes
- Imposter Syndrome: Diagnose Accurately Before Treating
- 2022 Top Story in Diabetes: Results of the GRADE Trial
- ADA 2022: Recommendations From Dr. Deborah Wexler
- 2021 Top Story in Diabetes: Empagliflozin for Heart Failure With Preserved Ejection Fraction
- Hemoglobin A1c Reduction and CV Risk Improvement: Correlation, Causation and Clinical Recommendations
- Rationale and Clinical Utility of Sulfonylureas in Contemporary Practice
- Comparative Effectiveness of a DPP-4 Inhibitor, a Sulfonylurea, a GLP-1 Agonist, and Basal Insulin: Data From the GRADE Trial